Mazdutide
Also known as Mazdutide · IBI362 · GLP-1/glucagon dual agonist
New
Reconstitution & dosing guide
10 mg vial — research phases, recon steps, and a live unit calculator.
Available sizes & price
Catalog only10mg x 10 vials
Mazdutide · Not in current stock
$65 / vial
Prices per vial · Research use only · Not medical advice.
Investigational oxyntomodulin-analog dual agonist of GLP-1 and glucagon receptors under late-stage development for obesity and metabolic disease.
How to picture it
A dual agonist in the GLP-1 / glucagon family. Picture combined appetite and insulin-tone signaling plus glucagon-linked energy-expenditure biology — two metabolic conversations at once: "eat less aggressively" and "spend energy differently." Breadth is the educational appeal in weight-management science.
Research focus & benefits
- Dual GLP-1/glucagon metabolic research
- Weight and energy-expenditure pathway interest
- Next-generation dual-agonist studies
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
Mazdutide is a once-weekly dual GLP-1R/GCGR agonist designed to combine appetite suppression with energy-expenditure and hepatic metabolic effects from glucagon receptor engagement. Phase 2/3 programs (notably in China) have reported substantial weight loss. Research vials are not licensed drug product.
Mechanism
Balanced dual agonism at GLP-1R and GCGR with prolonged pharmacokinetics suitable for weekly SC dosing. Glucagon component may increase energy expenditure and improve liver fat metrics beyond pure GLP-1 agents.
Research uses
- Phase 2/3 obesity weight-loss readouts
- Metabolic and liver-fat exploratory endpoints
- Dual-agonist comparison research vs GLP-1 mono agonists
Research dosing notes
Clinical trial titration schedules only. Research materials are not approved product.
Half-life / kinetics
Designed for once-weekly dosing (investigational)
Common research routes
Reported considerations
- GI effects typical of incretins
- Heart-rate and metabolic effects from glucagon component
- Investigational safety profile evolving
Contraindications / cautions
- Pregnancy
- Personal history requiring medical obesity care
Common research stacks
- Generally monotherapy in trials
Legal / access note
Investigational agent; not FDA-approved as of research catalog framing. Research peptides are not pharmaceutical mazdutide.